Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420192 | 0.87 | NMT1 (0.44) | NMT1MEN1KMT2ANMT2HSP90AA1 | |
| SCHEMBL4757632 | 0.87 | NMT1 (0.39) | CYP3A4GRM4NMT1MEN1KMT2A | |
| SCHEMBL4824313 | 0.84 | TLR7 (0.40) | MEN1KMT2ALMNA | |
| SCHEMBL4753495 | 0.83 | SMN1; SMN2 (0.43) | CYP3A4GRM4NMT1MEN1KMT2A | |
| SCHEMBL1486507 | 0.80 | TLR7 (0.47) | CYP3A4GRM4NMT1MEN1KMT2A | |
| SCHEMBL4757662 | 0.79 | ACSS2 (0.38) | CYP3A4GRM4NMT1MEN1KMT2A | |
| SCHEMBL1486639 | 0.79 | TLR7 (0.46) | CYP3A4GRM4MEN1KMT2AACSS2 | |
| SCHEMBL1486772 | 0.79 | TLR7 (0.54) | CYP3A4GRM4NMT1ACSS2NMT2 | |
| SCHEMBL1486736 | 0.78 | BRD4 (0.40) | NMT1MEN1KMT2AMAPTNMT2 | |
| SCHEMBL4817670 | 0.78 | TLR7 (0.41) | CYP3A4MEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605943-A4 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7163947-B2 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2006028451-A1 | 1-AMINO 1-H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1605943-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | CYP3A4 1657/4885GRM4 2083/4885HDAC3 836/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | CYP3A4 1657/4885GRM4 2083/4885HDAC3 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.